ClinicalTrials.Veeva

Menu
P

Preferred Research Partners, Inc. | Little Rock, AR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Daridorexant
Relamorelin
Atogepant
Linaclotide
Vonoprazan
JZP-110
SPN-812
Dapagliflozin
BMS-512148
CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 110 total trials
Locations recently updated

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Enrolling
Major Depressive Disorder
Other: Placebo
Drug: DT120

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: DT120

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized...

Active, not recruiting
Generalized Anxiety Disorder
Drug: DT120
Other: Placebo

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participant...

Active, not recruiting
Eosinophilic Esophagitis
Drug: Placebo
Drug: Vonoprazan

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severe...

Active, not recruiting
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Placebo
Drug: Eltrekibart

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompa...

Enrolling
Chronic Migraine
Drug: Atogepant
Drug: Placebo for Atogepant

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and se...

Enrolling
Major Depressive Disorder
Drug: Icalcaprant
Drug: Placebo for Icalcaprant

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Placebo-Matching Atogepant
Drug: Atogepant

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the tre...

Enrolling
Migraine
Drug: Placebo
Drug: Elismetrep

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as ev...

Active, not recruiting
Fibrosis, Liver
Nonalcoholic Steatohepatitis (NASH)
Drug: Rencofilstat
Drug: Placebo

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if b...

Enrolling
Sleep Disorders
Overweight and/or Obesity
Other: Placebo
Drug: Berobenatide

The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 followi...

Enrolling
Hypogonadism
Drug: Natesto

The purpose of this clinical trial is to collect more data about the effect of daridorexant in adults and elderly people with insomnia disorder.The t...

Enrolling
Insomia Disorder
Drug: Daridorexant
Drug: Placebo

This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical...

Invitation-only
Post Traumatic Stress Disorder
Drug: TSND-201

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD.Eligible participants will enter a 4-week Treatment Period where the...

Enrolling
Post Traumatic Stress Disorder
Drug: Placebo
Drug: TSND-201

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate...

Enrolling
Crohn's Disease
Drug: Duvakitug
Drug: Placebo

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of du...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Duvakitug

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only
Migraine Prophylaxis
Drug: Atogepant

Trial sponsors

AbbVie logo
Apnimed logo
Janssen (J&J Innovative Medicine) logo
Allergan logo
Ferring logo
Idorsia Pharmaceuticals logo
Shire logo
D
Jazz Pharmaceuticals logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems